Goodwin Procter LLP advised Vascular Biogenics Ltd. on the deal.Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT) announced the closing of its underwritten public offering of 6,901,790 ordinary…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Martina Bellini
…
This content is for Standard 1 Year members only. LoginJoin Now